menu
    • menu

    Company profile for Alzheon

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alzheon’s ALZ-801 is currently the only oral disease-modifying treatment in late-stage testing for Alzheimer’s disease. We believe that ALZ-801 has the potential to significantly slow or stop disease progression and even prevent the onset of symptoms. Development of ALZ-801, a well tolerated new treatment, is based on seven years of Alzheon research into the biology of AD and data from 2000 patients treated with its act...
    Alzheon’s ALZ-801 is currently the only oral disease-modifying treatment in late-stage testing for Alzheimer’s disease. We believe that ALZ-801 has the potential to significantly slow or stop disease progression and even prevent the onset of symptoms. Development of ALZ-801, a well tolerated new treatment, is based on seven years of Alzheon research into the biology of AD and data from 2000 patients treated with its active ingredient tramiprosate.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlzheonUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    111 Speen Street Suite 306 Framingham, MA 01701
    Telephone
    Telephone
    1-508-861-7709
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://alzheon.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014241744/en/Alzheon-Announces-Peer-Reviewed-Scientific-Publication-of-Results-from-Pivotal-APOLLOE4-Phase-3-Trial-of-Oral-ValiltramiprosateALZ-801-in-APOE44-Homozygous-Individuals-with-Early-Alzheimers-Disease

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Alzheon to Present ALZ-801 Data at AAIC Toronto
    Alzheon to Present ALZ-801 Data at AAIC Toronto

    15 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250715240263/en/Alzheon-to-Present-Insights-into-Oral-ValiltramiprosateALZ-801-Mode-of-Action-and-Clinical-Efficacy-at-Dedicated-Symposium-at-Alzheimers-Association-International-Conference-in-Toronto-on-July-30th-2025

    BUSINESSWIRE
    15 Jul 2025
    Share Share
    Alzheon’s amyloid-targeting pill fails another Ph 3 study in AD
    Alzheon’s amyloid-targeting pill fails another Ph 3 study in AD

    12 Apr 2025

    // ENDPTS

    https://endpts.com/alzheons-amyloid-targeting-pill-fails-another-alzheimers-phase-3/

    ENDPTS
    12 Apr 2025
    Share Share
    Alzheon To Present APOLLOE4 Ph3 Data At ADPD On April 1
    Alzheon To Present APOLLOE4 Ph3 Data At ADPD On April 1

    18 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250318710720/en/Alzheon-to-Present-Results-from-Pivotal-APOLLOE4-Phase-3-Trial-of-Oral-ValiltramiprosateALZ-801-at-Dedicated-Symposium-at-ADPD-Conference-in-Vienna-on-April-1st-2025

    BUSINESSWIRE
    18 Mar 2025
    Share Share
    Alzheon Publishes Two Papers Ahead Ph 3 Topline Data At ADPD
    Alzheon Publishes Two Papers Ahead Ph 3 Topline Data At ADPD

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225250957/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search